You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Jardiance

Showing 1 - 25 of 118
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

(PMS) of JARDIANCE in Chronic Heart Failure (CHF)

Recruiting
  • Heart Failure
  • Tokyo, Japan
    Nippon Boehringer Ingelheim Co., Ltd.
Aug 10, 2022

JARDIANCE® Tablets in Japanese Type 2 Diabetes Mellitus

Completed
Has Results
  • Diabetes Mellitus, Type 2
  • Jardiance
  • Multiple Locations, Japan
    (unnamed)
Dec 2, 2021

Kidney Failure, Chronic, Heart Failure Trial in Jackson (Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing,

Not yet recruiting
  • Kidney Failure, Chronic
  • Heart Failure
  • Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing
  • Empagliflozin 10 mg daily dosing
  • Jackson, Mississippi
    University of Mississippi Medical Center
Jan 19, 2023

Metabolic-associated Fatty Liver Disease, Type 2 Diabetes Trial (Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide)

Not yet recruiting
  • Metabolic-associated Fatty Liver Disease
  • Type 2 Diabetes
  • (no location specified)
Oct 1, 2022

Jardiance® Post Marketing Surveillance in Korean Chronic Heart

Recruiting
  • Heart Failure
  • Anyang-si, Gyeonggi-do, Korea, Republic of
  • +19 more
Jan 10, 2023

Emp-Activity: Empagliflozin Functional Capacity

Not yet recruiting
  • Heart Failure
  • (no location specified)
Aug 5, 2022

Obesity, Metabolic Syndrome Trial in Nashville (Empagliflozin 25 MG, Placebo)

Not yet recruiting
  • Obesity
  • Metabolic Syndrome
  • Empagliflozin 25 MG
  • Placebo
  • Nashville, Tennessee
    Vanderbilt University Medical Center
Jul 24, 2023

Heart Failure With Preserved Ejection Fraction Trial in Philadelphia (Empagliflozin + Potassium Chloride, Empagliflozin +

Recruiting
  • Heart Failure With Preserved Ejection Fraction
  • Empagliflozin + Potassium Chloride
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania Health System
May 25, 2022

Type 2 Diabetes, Type 1 Diabetes Trial in San Antonio (Empagliflozin 25 MG, Placebo)

Not yet recruiting
  • Type 2 Diabetes
  • Type 1 Diabetes
  • Empagliflozin 25 MG
  • Placebo
  • San Antonio, Texas
    Texas Diabetes Institute/UH
Jul 31, 2023

Glycogen Storage Disease Type IB Trial in Shanghai (Empagliflozin)

Recruiting
  • Glycogen Storage Disease Type IB
  • Shanghai, Shanghai, China
    Xinhua Hospital, Shanghai Jiao Tong University School of Medicin
Jul 17, 2023

Heart Failure, Reduced Ejection Fraction Heart Failure Trial in Damanhur (Empagliflozin 10 MG, Dapagliflozin 10 MG)

Recruiting
  • Heart Failure
  • Reduced Ejection Fraction Heart Failure
  • Empagliflozin 10 MG
  • Dapagliflozin 10 MG
  • Damanhūr, Elbehairah, Egypt
    Damanhour Teaching Hospital, General Organization for Teaching H
Oct 3, 2023

Comparative Effectiveness of Empagliflozin in the US

Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Boston, Massachusetts
    Bringham Women Hospital
Jan 9, 2023

Cystic Fibrosis-related Diabetes, Cystic Fibrosis Trial in Minneapolis (Empagliflozin, Placebo Control)

Not yet recruiting
  • Cystic Fibrosis-related Diabetes
  • Cystic Fibrosis
  • Minneapolis, Minnesota
    University of Minnesota
Nov 20, 2023

Heart Failure With Preserved Ejection Fraction, Microvascular Dysfunction Trial in Maastricht (Participants receive 10mg

Recruiting
  • Heart Failure With Preserved Ejection Fraction
  • Microvascular Dysfunction
  • Participants receive 10mg Empaglifozin once daily on prescription from their treating physician. This is not an intervention in this trial, but part of their normal HFpEF treatment
  • Maastricht, Limburg, Netherlands
    Maastricht University Hospital
Sep 13, 2023

MDD Trial in New York (Empagliflozin)

Not yet recruiting
  • Major Depressive Disorder
  • New York, New York
    NYU Langone Health
Feb 24, 2023

Healthy Trial in Goiânia (empagliflozin/metformin, Jardiance®, Glifage®)

Completed
  • Healthy
  • Goiânia, Brazil
    Instituto de Ciências Farmacêuticas de Estudos e Pesquisas - ICF
Oct 29, 2021

End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis Trial (Empagliflozin, Placebo)

Not yet recruiting
  • End-stage Kidney Disease
  • +7 more
  • (no location specified)
Jan 9, 2023

SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac

Recruiting
  • Coronary Artery Disease
  • Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
  • Shah Alam, Selangor, Malaysia
    Institute for Clinical Research, National Institutes of Health,
Nov 9, 2023

Epilepsy Trial in Saint Louis (Empagliflozin 25 mg, Placebo)

Recruiting
  • Epilepsy
  • Empagliflozin 25 mg
  • Placebo
  • Saint Louis, Missouri
    Washington University
Aug 20, 2022

Korean Type 2 Diabetes Mellitus

Completed
Has Results
  • Diabetes Mellitus, Type 2
  • JARDIANCE 10mg
  • JARDIANCE 25mg
  • Multiple Locations, Korea, Republic of
    (unnamed)
Apr 15, 2021

Type2 Diabetes Trial in Amsterdam (EMPA/LINA 10/5 mg QD (n=22), LINA/EMPA 5/10 mg QD (N=22), Gliclazide 30 mg QD/BID (N=22))

Active, not recruiting
  • Type2 Diabetes
  • EMPA/LINA 10/5 mg QD (n=22)
  • +2 more
  • Amsterdam, Noord-Holland, Netherlands
    VU University Medical Center
Jan 13, 2022

Type 2 Diabetes Trial in Seoul (Teneligliptin, Empagliflozin, Teneligliptin and Empagliflozin)

Completed
  • Type 2 Diabetes Mellitus
  • Seoul, Korea, Republic of
    Clinical Pharmacology, Asan Medical Center
Nov 8, 2021

Tricuspid Regurgitation, Right Ventricular Dilatation Trial in Seoul (Carvedilol+Empagliflozin, Carvedilol, Empagliflozin)

Recruiting
  • Tricuspid Regurgitation
  • Right Ventricular Dilatation
  • Seoul, Korea, Republic of
  • +2 more
Feb 14, 2022

PreDiabetes, Prediabetic State, Overweight and Obesity Trial in Corvallis (Empagliflozin, Multivitamin-Placebo)

Recruiting
  • PreDiabetes
  • +2 more
  • Corvallis, Oregon
    Oregon State University
Jul 19, 2022

Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors Trial in Toronto

Not yet recruiting
  • Peritoneal Dialysis Complication
  • +4 more
  • Empagliflozin 25 MG
  • Toronto, Ontario, Canada
    Toronto General Hospital
Jan 27, 2023